Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
SILO
Silo Pharma, Inc.
CAPPED RATING
Silo Pharma, Inc. (SILO) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.3
/ 5.0
C
Value
B-
Factor Score
3.1
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
C-
Factor Score
2.0
/ 5.0
Momentum
D-
Factor Score
1.0
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-2.6
EV / EBITDA
0.5
Rev Growth YoY
N/A
Gross Margin
-14.8%
Price Return 3M
-40.1%
Price Return 12M
-72.8%
Catalyst Signal
0.00
Market Cap
$4.3M
TTM Revenue
$54.1K
Price / Sales
79.6
ROE
-91.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.1) | C+ (2.5) | C- (2.0) | D- (1.0) | C+ (2.6) | C (2.3) |
| 2026-11-07 | B (3.3) | C+ (2.5) | C- (2.0) | F (0.6) | C+ (2.7) | C (2.2) |
| 2026-10-31 | B (3.2) | C+ (2.5) | C- (1.9) | F (0.5) | C+ (2.7) | C- (2.1) |
| 2026-10-24 | B (3.2) | C+ (2.5) | D+ (1.8) | F (0.5) | C+ (2.6) | C- (2.1) |
| 2026-10-17 | B (3.2) | C+ (2.5) | D+ (1.8) | F (0.4) | C+ (2.6) | C- (2.1) |
Page
1
of
4